AMI-1
CAS No. 20324-87-2
AMI-1 ( AMI-1 | AMI 1 | AMI1 | AMI-1 disodium salt. )
产品货号. M13165 CAS No. 20324-87-2
PRMT(蛋白质精氨酸甲基转移酶)的特异性抑制剂,但不是赖氨酸甲基转移酶。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥348 | 有现货 |
|
| 10MG | ¥518 | 有现货 |
|
| 25MG | ¥1037 | 有现货 |
|
| 50MG | ¥1531 | 有现货 |
|
| 100MG | ¥2406 | 有现货 |
|
| 500MG | ¥5816 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称AMI-1
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述PRMT(蛋白质精氨酸甲基转移酶)的特异性抑制剂,但不是赖氨酸甲基转移酶。
-
产品描述A specific inhibitor of PRMTs (protein arginine methyltransferases), but not lysine methyltransferases; inhibits PRMT1 and Hmt1p with IC50s of 8.81 uM and 3.03 uM respectively; increases the ratio of Bax/Bcl-2, and leads to apoptosis and loss of migratory activity in several HCC cells,decreases the expression levels of H4R3me2s; strongly inhibits HCC growth in vivo.
-
体外实验AMI-1 can inhibit the in vitro methylation reactions performed by all five recombinantly active PRMTs (PRMT1, -3, -4, and -6 and Hmt1p).AMI-1 not only inhibits type I PRMTs (PRMT1, 3, 4 and 6) but also type II PRMT5. AMI-1 specifically inhibits arginine, but not lysine, methyltransferase activity in vitro and does not compete for the AdoMet binding site. AMI-1 inhibits methylation of GFP-Npl3 and cellular proteins.AMI-1 (0.6-2.4 mM; 48-96 hours) inhibits the cell viability of sarcoma in S180 and U2OS cells in a time-dependent and dose-dependent manner in vitro.AMI-1 (1.2-2.4 mM; 48-72 hours) reduces S180 cell viability through the induction of cell apoptosis. Cell Viability Assay Cell Line:S180 cells, U2OS cells Concentration:0.6 mM, 1.2 mM, 2.4 mM Incubation Time:48 hours, 72 hours, 96 hours Result:Inhibited the cell viability.Apoptosis AnalysisCell Line:S180 cellsConcentration:1.2 mM, 2.4 mM Incubation Time:48 hours, 72 hours Result:Increased the percentages of cells undergoing apoptosis.
-
体内实验AMI-1 (0.5 mg; intratumorally; daily; for 7 days) inhibits S180 viability in vivo.AMI-1 (0.5 mg; intratumorally; daily; for 7 days) downregulates PRMT5 but does not regulate the expression of PRMT7 in a tumor xenograft model.AMI-1 (0.5 mg; intratumorally; daily; for 7 days) decreases the levels of H4R3me2s and H3R8me2s in a tumor xenograft model. Animal Model:6-7 weeks old male Kunming mice (18-22 g), with S180 cells xenograft Dosage:0.5 mg Administration:Intratumorally, daily, for 7 days Result:Decreased tumor weight.
-
同义词AMI-1 | AMI 1 | AMI1 | AMI-1 disodium salt.
-
通路Chromatin/Epigenetic
-
靶点HMTase
-
受体PRMT1|yeastHmt1p
-
研究领域Inflammation/Immunology
-
适应症——
化学信息
-
CAS Number20324-87-2
-
分子量548.4534
-
分子式C21H14N2Na2O9S2
-
纯度>98% (HPLC)
-
溶解度DMSO: ≥ 46 mg/mL
-
SMILESO=C(NC1=CC2=CC(S(=O)([O-])=O)=CC(O)=C2C=C1)NC3=CC4=CC(S(=O)([O-])=O)=CC(O)=C4C=C3.[Na+].[Na+]
-
化学全称2-Naphthalenesulfonic acid, 7,7'-(carbonyldiimino)bis[4-hydroxy-, sodium salt (1:2)
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Cheng D, et al. J Biol Chem. 2004 Jun 4;279(23):23892-9.
2. Zhang B, et al. Oncotarget. 2015 Sep 8;6(26):22799-811.
3. Zhang B, et al. J Transl Med. 2015 Nov 5;13:349.
021-51111890
购物车()
sales@molnova.cn

